Agency / Source: STEMCELL Technologies, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Molecular Devices and STEMCELL Technologies Collaborate to Accelerate Adoption of Human-Relevant Organoid Models through Automation - Validated on the CellXpress.ai® Automated Cell Culture System, the new workflow combines organoid biology expertise and laboratory automation to help researchers reduce variability, expand scale, and move discoveries toward impact with greater confidence
Molecular Devices and STEMCELL Technologies Collaborate to Accelerate Adoption of Human-Relevant Organoid Models through Automation

 

PRZOOM - /newswire/ - San Jose, CA, United States, 2026/09/15 - Validated on the CellXpress.ai® Automated Cell Culture System, the new workflow combines organoid biology expertise and laboratory automation to help researchers reduce variability, expand scale, and move discoveries toward impact with greater confidence.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Molecular Devices, a Danaher company and a leading provider of high-performance life science solutions, and STEMCELL Technologies (STEMCELL), a global supplier of specialized products and services supporting life sciences, today announced a validated automated workflow that can be used with STEMCELL's IntestiCult™ Plus Organoid Growth Medium for human intestinal organoids culture on the Molecular Devices CellXpress.ai Automated Cell Culture System. Available as a downloadable protocol, the workflow provides researchers with a ready-to-implement approach to automating organoid culture, helping reduce hands-on time and experimental variability while enabling more consistent, scalable generation of human-relevant research models and accelerating discovery.

The workflow marks the first milestone in a strategic collaboration to automate STEMCELL's portfolio of organoid culture kits on the CellXpress.ai system. By combining STEMCELL's expertise in organoid biology with Molecular Devices' automation capabilities, the companies aim to help researchers more easily adopt and scale human-relevant models, reducing barriers to implementation and accelerating research workflows in laboratories worldwide. Under the collaboration, Molecular Devices develops and validates automated workflows, while STEMCELL provides tissue-specific scientific expertise for performance criteria and cell-based functional characterization to support protocol development and validation.

"Organoids have the potential to give researchers a more human-relevant view of disease and treatment response, but their broader use depends on making these models easier to implement at scale," said Mary Duseau, President of Molecular Devices. "This collaboration is an important step toward giving more scientists practical access to advanced cellular models while freeing them to focus on the biological questions that can inform the development of better therapies."

The workflow enables automated culture, monitoring, and analysis of human intestinal organoids within a standardized process on the CellXpress.ai system. Researchers can implement the validated protocol as provided or adapt it to meet specific experimental requirements, providing flexibility for a range of organoid research applications.

"This collaboration helps make advanced organoid workflows more accessible to scientists working across drug discovery, disease research, and translational biology," said Dr. Allen Eaves, President and CEO of STEMCELL Technologies. "Together, we're enabling researchers to combine well-established organoid culture systems with automation, supporting the adoption of new approach methodologies (NAMs) and making it easier to generate reproducible results and scale their work as research needs evolve."

The companies plan to evaluate additional organoid models and workflows for automation on the CellXpress.ai system, creating a growing portfolio of validated applications for drug discovery, disease modeling, toxicology, and translational research. The collaboration reflects a shared commitment to helping researchers integrate more human-relevant models into laboratory workflows while reducing operational barriers to adoption and scale. Learn more here.

About Molecular Devices, LLC

Molecular Devices (moleculardevices.com), a Danaher Company, is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe.

Molecular Devices is proud to be a part of Danaher. Visit Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

About STEMCELL Technologies

STEMCELL Technologies (stemcell.com) supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally. Based in Vancouver, British Columbia, STEMCELL is Canada's largest biotechnology company. Driven by a love of science and a passion for quality, STEMCELL is a company of Scientists Helping Scientists.

Media Contact: Amy Smith, Molecular Devices
P: 408-334-4699 - E: amy.smith[.]moldev.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Molecular Devices and STEMCELL Technologies Collaborate to Accelerate Adoption of Human-Relevant Organoid Models through Automation

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Molecular Devices, LLC | STEMCELL Technologies
Contact: Press Office - Stemcell.com 
public.relations[.]stemcell.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From STEMCELL Technologies, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ono Pharma Receives Orphan Medicinal Product Designation for Sapablursen from EC and Plans to Present Trial-in-Progress Poster At ASH 2026
Ono Pharma Announces Results from Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator
NEC Contributes to AI Powered Vaccine Design through the EU Funded PREPAIR VAC Pandemic Preparedness Project
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 At ESMO 2026
Frost & Sullivan Awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership
Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN
Ono Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures
ZAGENO Earns Frost & Sullivan’s 2026 North American Life Sciences E‑Commerce Company of the Year Recognition
SCHOTT Pharma, Takeda and Corplex Bring Closed-loop Recycling System for Pharmaceutical Vial Trays into Operations
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS | 
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today